Role of Endoscopic Ultrasound-guided Gastroenterostomy for Benign Gastric Outlet Obstruction Suprabhat Giri, Saroj Kanta Sahu, Gaurav Khatana, Prasanna Gore, Preetam Nath, Bipadabhanjan Mallick, Jimmy Narayan, Aditya Kale, Sridhar Sundaram Den Open, 2026 Benign gastric outlet obstruction (GOO) often results from intrinsic conditions like peptic strictures, caustic‐induced stricture, and surgical anastomoses, and extrinsic conditions like pancreatitis, hematoma, and superior mesenteric artery syndrome. While traditional management involved surgery or endoscopic balloon dilation, endoscopic ultrasound‐guided gastroenterostomy (EUS‐GE) has emerged as a minimally invasive alternative using lumen‐apposing metal stents (LAMS). We aimed to summarize the currently available literature on EUS‐GE in treating benign GOO. EUS‐GE demonstrates high technical success rates, ranging from 95% to 100%, and significant clinical success, typically exceeding 80% in patients with benign GOO. It offers advantages by bypassing the obstruction and potentially providing longer‐lasting relief compared to enteral stenting without the morbidity of surgery. Furthermore, it can serve as a bridge to definitive treatment, allowing for nutritional optimization before surgery or resolution of the underlying condition with subsequent stent removal in a notable proportion of patients. Despite the high efficacy, EUS‐GE is associated with multiple adverse events like maldeployment, bleeding, and ascites with or without infection. Thus, EUS‐GE is a promising and effective minimally invasive modality for managing benign GOO, particularly in patients who fail conventional endoscopic therapies or are poor surgical candidates. However, current evidence is limited by the retrospective nature of many studies, small sample sizes, and the need for longer‐term follow‐up to assess stent durability and the optimal management of indwelling LAMS. Larger prospective studies are warranted to further define the role of EUS‐GE in benign GOO and compare it with other treatment strategies.
Burden of inflammatory bowel disease in India: analysis of the Global Burden of Disease study from 1990 to 2019 Suprabhat Giri, Anuraag Jena, Praveen Kumar-M, Jaikumar Rajavoor Muniswamy, Preetam Nath, Vishal Sharma Intestinal Research, 2026 Background/Aims: Inflammatory bowel disease (IBD) is increasing across the globe, more so in populous countries like India. We aimed to study the disease burden and epidemiological trends of IBD in India and look closer into the disease pattern across the country from 1990 to 2019. Methods: The burden of IBD was estimated in India using the data from the Global Burden of Disease estimate for 2019, which is a comprehensive worldwide project. The analysis included various parameters like incidence, prevalence, mortality, disability-adjusted life years, years lived with disability, and years of life lost as age-adjusted rates (per 100,000 population). Using modeling, the prediction was also made for 2050 in India. Results: The age-standardized incidence, prevalence, mortality, and disability rates of IBD in India for 2019 were 2.34, 20.34, 0.40, and 13.04, respectively. These are lower than the global incidence, prevalence, mortality, and disability rates of 4.97, 59.25, 0.54, and 20.15, respectively. The annual rates of change in incidence, prevalence, mortality, and disability rates in India from 1990 to 2019 were 0.05, –0.02, –0.36, and –0.35, respectively. The annual rates of change in incidence and prevalence are higher than the global rate of –0.18 and –0.19, while the annual rates of change in mortality and disability are lower than the global rate of –0.19 and –0.26. Conclusions: The incidence and prevalence of IBD in India are lower compared to the global population but are increasing at a faster rate than the global population.
Incidence, Predictors, Management, and Outcome of Paralytic Ileus in Acute Pancreatitis Suprabhat Giri, Chandramauli Mishra, Sukhraj Pal Singh, Saroj Kanta Sahu, Dibya Lochan Praharaj, Bipadabhanjan Mallick, Preetam Nath, Swati Das, Vedavyas Mohapatra, Sarat Chandra Panigrahi, Anil Chandra Anand, Manoj Kumar Sahu, Enrique de-Madaria Pancreas, 2026 Background: Paralytic ileus is a frequent complication of acute pancreatitis (AP), contributing to increased morbidity, nutritional compromise, and risk of infection. Despite its clinical relevance, data on its incidence, predictors, management, and outcomes in AP remain limited. Methods: We conducted a retrospective study of 426 adult patients admitted with AP over a 3-year period at a tertiary-care center. The primary outcome was paralytic ileus; secondary outcomes included infected necrosis, intervention, and mortality. Multivariate logistic regression identified independent predictors expressed as adjusted odds ratio (aOR). Results: Paralytic ileus occurred in 167/426 (39.2%) patients. Patients with ileus were more frequently male, obese, and had higher rates of SIRS compared with those without ileus. They also exhibited significantly higher leukocyte counts, neutrophil-lymphocyte ratio (NLR), serum creatinine, and lower serum albumin and sodium levels. In multivariate analysis, obesity (aOR: 2.329), NLR (aOR: 1.131), serum albumin (aOR: 0.342), and serum sodium (aOR: 0.802) were identified as independent predictors. An NLR of 9.5 had a sensitivity of 82.6% and a specificity of 76.1% for predicting paralytic ileus. Conservative management resolved ileus in 85% of cases, 6% responded to neostigmine, while 9% with unresolved ileus succumbed to multiorgan failure. Paralytic ileus was independently associated with increased risk of infected necrosis (aOR: 3.62), intervention (aOR: 4.43), and mortality (aOR: 4.71). Conclusion: Paralytic ileus affects a significant proportion of patients with moderate to severe AP and is a marker of local and systemic complications. Paralytic ileus was an independent predictor of infected necrosis, intervention, and mortality, underscoring its prognostic relevance.
Vonoprazan in Management of Refractory Gastroesophageal Reflux Disease: An Indian Expert Group Consensus Statements Philip Abraham, Gouradas Choudhuri, Sharad Deshmukh, Manish Kak, Mangesh Tiwaskar, Rakesh Kochhar, SK Sinha, SC Panigrahi, Rajeev Shandil, Molina Khanna, Ramesh Garg, GS Lamba, Monika Jain, Prateik Poddar, Ajay Mishra, Apurva Shah, Chetan Kantharia, Hardik Shah, Indraneel Saha, Khurshid Vazifdar, Lokesh Jain, Nitin Borse, Pallavi Garg, Manoj Kumar, Manoj Sahu, Preetam Nath, Rajdeep Singh, Vikram Sahu, Sanjay Bandyopadhyay, Saurabh Jaiswal, Dinesh Patil, Shripad Bodas, Smit Vaghasia, Sudeep Khanna, Onkar C Swami, Suneel Chakravarty, Vamsi Murthy K, Vinod Kumar Journal of Association of Physicians of India, 2025 BACKGROUND Approximately, 40% of gastroesophageal reflux disease (GERD) patients experience insufficient symptom relief from proton-pump inhibitors (PPI), resulting in PPI-refractory GERD (rGERD). OBJECTIVE To review the existing literature and develop an Indian expert group consensus statement on the place of vonoprazan in the management of rGERD. MATERIALS AND METHODS A panel of 35 leading Indian gastroenterologists extensively reviewed the literature to develop consensus statements for the management of rGERD in Indian patients, with a focus on the newly available potassium-competitive acid blocker (P-CAB), vonoprazan. This process involved two structured meetings in which experts deliberated on literature reviews and draft statements, which were further rigorously discussed and modified. Consensus was achieved through a voting process employing a five-point Likert scale, with results meticulously documented. The final statements unanimously approved by all participants and subsequently developed into a comprehensive manuscript. RESULTS Based on the evidence, 14 statements were developed and confirmed by expert panelists for the assessment and management of rGERD. Among these 14 statements, 5 obtained Level A evidence, 4 received Level B, 4 were classified as Level C, and 1 as Level D. The consensus highlights the importance of symptom assessment, lifestyle modifications, and medication adherence, followed by a diagnostic procedure with upper gastrointestinal (GI) endoscopy. If needed, manometry or 24-hour pH impedance may be considered. Vonoprazan, a novel and reversible potassium-competitive acid blocker (P-CAB), has emerged as a potential alternative to proton pump inhibitors (PPIs), offering rapid, potent, and sustained acid suppression. Based on current evidence, a daily dose of 20 mg vonoprazan for 4-8 weeks is recommended as an initial treatment strategy for rGERD. CONCLUSION The consensus endorses the use of vonoprazan to improve patient outcomes and quality of life, highlighting its important place in therapy for controlling rGERD in Indian patients.
Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) Ajay Duseja, S.P. Singh, Arka De, Kaushal Madan, Padaki Nagaraja Rao, Akash Shukla, Gourdas Choudhuri, Sanjiv Saigal, Shalimar, Anil Arora, Anil C. Anand, Ashim Das, Ashish Kumar, Chundamannil E. Eapen, Krishnadas Devadas, Kotacherry T. Shenoy, Manas Panigrahi, Manav Wadhawan, Manish Rathi, Manoj Kumar, Narendra S. Choudhary, Neeraj Saraf, Preetam Nath, Sanjib Kar, Seema Alam, Samir Shah, Sandeep Nijhawan, Subrat K. Acharya, Vinayak Aggarwal, Vivek A. Saraswat, Yogesh K. Chawla Journal of Clinical and Experimental Hepatology, 2023
Hook Worm Infestation in a Neonate Dibya L. Praharaj, Bipadabhanjan Mallick, Preetam Nath, Palash Das Journal of Pediatric Gastroenterology and Nutrition, 2022
Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure Florence Wong, Salvatore Piano, Virendra Singh, Michele Bartoletti, Rakhi Maiwall, Carlo Alessandria, Javier Fernandez, Elza Cotrim Soares, Dong Joon Kim, Sung Eun Kim, Monica Marino, Julio Vorobioff, Rita de Cassia Ribeiro Barea, Manuela Merli, Laure Elkrief, Victor Vargas, Aleksander Krag, Shivaram Prasad Singh, Laurentius Adrianto Lesmana, Claudio Toledo, Sebastian Marciano, Xavier Verhelst, Nicolas Intagliata, Liane Rabinowich, Luis Colombato, Sang Gyune Kim, Alexander Gerbes, Francois Durand, Juan Pablo Roblero, Tony Bruns, Eileen Laurel Yoon, Marcos Girala, Nikolaos T. Pyrsopoulos, Tae Hun Kim, Sun Young Yim, Adria Juanola, Adrian Gadano, Paolo Angeli, Kalyan Bhamidimarri, Thomas D. Boyer, Carlos Brodersen, Daniela Campion, Paolo Caraceni, Robert A. de Man, Eduardo Fassio, Annette Dam Fialla, Carmine Gambino, Vikas Gautam, Pere Gines, Jae Seok Hwang, Hyoung Su Kim, Jeong Han Kim, Pramod Kumar, Barbara Lattanz, Tae Hee Lee, Cosmas A. Rinaldi Lesmana, Marina Maevskaya, Preetam Nath, Gustavo Navarro, Ji-Won Park, Gisela Pinero, Sophie Restellini, Gustavo Romero, Tiago Sevá -Pereira, Macarena Simón-Talero, Do Seon Song, Ki Tae Suk, Hans Van Vlierberghe, Giacomo Zaccherini Journal of Hepatology, 2021
Lymphadeno-duodenal fistula in tuberculosis Bipadabhanjan MALLICK, Dibya L PRAHARAJ, Preetam NATH, Sarat C PANIGRAHI, Anil C ANAND Arquivos Brasileiros De Cirurgia Digestiva, 2021
Indian National Association for the Study of Liver Consensus Statement on Acute Liver Failure (Part-2): Management of Acute Liver Failure A. Anand, B. Nandi, S. Acharya, A. Arora, S. Babu, Y. Batra, Y. Chawla, A. Chowdhury, Ashok Chaoudhuri, Eapen C. Eapen, H. Devarbhavi, R. Dhiman, S. Datta Gupta, A. Duseja, D. Jothimani, D. Kapoor, P. Kar, M. S. Khuroo, Ashish Kumar, K. Madan, B. Mallick, R. Maiwall, N. Mohan, A. Nagral, P. Nath, S. C. Panigrahi, Ankush Pawar, C. Philips, Dibyalochan Prahraj, P. Puri, A. Rastogi, V. Saraswat, S. Saigal, Shalimar, A. Shukla, S. Singh, T. Verghese, M. Wadhawan Journal of Clinical and Experimental Hepatology, 2020
Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis Anil C. Anand, Bhaskar Nandi, Subrat K. Acharya, Anil Arora, Sethu Babu, Yogesh Batra, Yogesh K. Chawla, Abhijit Chowdhury, Ashok Chaoudhuri, Eapen C. Eapen, Harshad Devarbhavi, RadhaKrishan Dhiman, Siddhartha Datta Gupta, Ajay Duseja, Dinesh Jothimani, Dharmesh Kapoor, Premashish Kar, Mohamad S. Khuroo, Ashish Kumar, Kaushal Madan, Bipadabhanjan Mallick, Rakhi Maiwall, Neelam Mohan, Aabha Nagral, Preetam Nath, Sarat C. Panigrahi, Ankush Pawar, Cyriac A. Philips, Dibyalochan Prahraj, Pankaj Puri, Amit Rastogi, Vivek A. Saraswat, Sanjiv Saigal, Shalimar, Akash Shukla, Shivaram P. Singh, Thomas Verghese, Manav Wadhawan Journal of Clinical and Experimental Hepatology, 2020
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide Salvatore Piano, Virendra Singh, Paolo Caraceni, Rakhi Maiwall, Carlo Alessandria, Javier Fernandez, Elza Cotrim Soares, Dong Joon Kim, Sung Eun Kim, Monica Marino, Julio Vorobioff, Rita de Cassia Ribeiro Barea, Manuela Merli, Laure Elkrief, Victor Vargas, Aleksander Krag, Shivaram Prasad Singh, Laurentius Adrianto Lesmana, Claudio Toledo, Sebastian Marciano, Xavier Verhelst, Florence Wong, Nicolas Intagliata, Liane Rabinowich, Luis Colombato, Sang Gyune Kim, Alexander Gerbes, Francois Durand, Juan Pablo Roblero, Kalyan Ram Bhamidimarri, Thomas D. Boyer, Marina Maevskaya, Eduardo Fassio, Hyoung Su Kim, Jae Seok Hwang, Pere Gines, Adrian Gadano, Shiv Kumar Sarin, Paolo Angeli, Michele Bartoletti, Carlos Brodersen, Tony Bruns, Robert A. de Man, Annette Dam Fialla, Carmine Gambino, Vikas Gautam, Marcos Girala, Adria Juanola, Jeong Han Kim, Tae Hun Kim, Pramod Kumar, Barbara Lattanzi, Tae Hee Lee, Cosmas A. Rinaldi Lesmana, Richard Moreau, Preetam Nath, Gustavo Navarro, Ji-Won Park, Gisela Pinero, Nikolaos T. Pyrsopoulos, Sophie Restellini, Gustavo Romero, Marco Sacco, Tiago Sevá-Pereira, Macarena Simón-Talero, Do Seon Song, Ki Tae Suk, Hans Van Vlierberghe, Sun Young Yim, Eileen Laurel Yoon, Giacomo Zaccherini Gastroenterology, 2019
